Abstract PD4-04: Updated results of tucatinib vs placebo added to trastuzumab and capecitabine for patients with previously treated HER2-positive metastatic breast cancer with brain metastases (HER2CLIMB)
Nancy U. Lin(Dana-Farber Cancer Institute), Eric P. Winer(University of Vermont), David Cameron(Corewell Health), Sherene Loi(The University of Melbourne), Carey K. Anders(Duke University), Dennis J. Slamon(University of California, Los Angeles), Gabriel Hortobagyi(The University of Texas MD Anderson Cancer Center), Michael P. DiGiovanna(Goethe University Frankfurt), Rashmi K. Murthy(The University of Texas MD Anderson Cancer Center), Mark D. Pegram(Stanford University), Ian E. Krop(Yale Cancer Center), Jorge Ramos(Seagen (United States)), Amelia Zelnak(Northside Hospital), Philippe L. Bédard(Princess Margaret Cancer Centre), Lisa A. Carey(University of North Carolina at Chapel Hill), Mafalda Oliveira(Vall d'Hebron Institut de Recerca), Wentao Feng(Seagen (United States)), Karen A. Gelmon(University of British Columbia), Sara A. Hurvitz(University of Washington), A Jo Chien, Vandana G. Abramson(Vanderbilt University), Sibylle Loibl(Goethe University Frankfurt), Thomas Bachelot(Centre Léon Bérard), Volkmar Müller(Universität Hamburg), Virginia F. Borges(University of Colorado Anschutz Medical Campus), Elisavet Paplomata(Cancer Research UK), Giuseppe Curigliano(European Institute of Oncology)
Cited by 7
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k